Abbott Laboratories Stock News

The Russian invasion of Ukraine seems to have set off a reinvigorated bout of volatility in the markets.

You can buy and hold these stable stocks forever.

This can largely be attributed to its recent voluntary recall of three types of baby formula - Similac, Alimentum, and EleCare - all manufactured in its Sturgis plant and with an expiration of April 1

Abbott (ABT) closed the most recent trading day at $117.25, moving -0.22% from the previous trading session.

The U.S. FDA has granted Abbott Laboratories (ABT) an expanded indication for the CardioMEMS HF System which will allow an additional 1.2M people access to the product.

Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

These stocks will take your wealth to the next level while letting you sleep well at night.

Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.

The FDA has approved an expanded indication for Abbott Laboratories'' (NYSE: ABT ) CardioMEMS HF System. The CardioMEMS HF System was initially approved in 2014 for use in New York Heart Association (NYHA) Class III heart failure patients with a prior heart failure hospitalization within the last year. The new indication allows the CardioMEMS sensor to be used by people living with Class II Full story available on Benzinga.com

WASHINGTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Prostate Specific Antigen (PSA) Testing Market finds that rising prostate cancer among men, who are over 50 years in age is augmenting the growth of Prostate Specific Antigen (PSA) Testing Market in the coming years. In addition, various inventions for the diagnosis of prostate cancer and development of various assay-based methods have increased the demand for PSA testing. This improved technology is used to provide accuracy and specificity of the results, thus, helps in improving the Prostate Specific Antigen (PSA) Testing Market demand. The total Global Prostate Specific Antigen (PSA) Testing Market is estimated to reach USD 5.83 Billion by 2028. The market stood at a revenue of USD 3.12 Billion in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 11.2%, states Vantage Market Research, in a report, titled " Prostate Specific Antigen (PSA) Testing Market by Test Type (Preliminary Tests, Confirmatory Tests), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

These stocks will take your wealth to the next level while letting you sleep well at night.

Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.

Abbott Laboratories recently became a Dividend King.